AtriCure Inc (NAS:ATRC)
$ 23.76 2.565 (12.1%) Market Cap: 1.15 Bil Enterprise Value: 1.12 Bil PE Ratio: 0 PB Ratio: 2.52 GF Score: 66/100

AtriCure Inc CONVERGE Trial Results -- Investor and Analyst Discussion Transcript

May 08, 2020 / 05:00PM GMT
Release Date Price: $45.06 (+7.70%)
Operator

Good afternoon and welcome to AtriCure's Investor and Analyst Meeting in conjunction with HRS. My name is Stacy, and I will be your coordinator for the call today. (Operator Instructions) We will be facilitating a question-and-answer session toward the end of today's call. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Lynn Lewis from Gilmartin Group for a few introductory comments.

Lynn Pieper Lewis
Gilmartin Group LLC - Founder & CEO

Thank you so much. Before we begin today, I'd like to remind everyone that as part of today's call, we will make certain comments about AtriCure's future expectations, plans and prospects that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, expectations regarding the timing of FDA review, expectations regarding FDA's response and whether it will approve CONVERGE, the potential CONVERGE launch timing, the potential market opportunities for CONVERGE and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot